Feedback PLC First GE Healthcare order for TexRAD®
15 August 2018 - 8:00AM
RNS Non-Regulatory
TIDMFDBK
Feedback PLC
15 August 2018
Feedback plc
First GE Healthcare order for TexRAD(R) medical imaging
software
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the
specialist medical imaging technology company, announces that its
operating company Feedback Medical Ltd has received its first order
via GE Healthcare (GEHC) for TexRAD(R) , its patented image texture
analysis technology.
The order follows the distribution agreement announced on 25
April 2018, granting GEHC non-exclusive global rights to offer
TexRAD(R) for medical imaging research applications.
The TexRAD(R) software purchase is for the Post Graduate
Institute of Medical Education & Research, Chandigarh, India.
TexRAD(R) software is currently used in over 50 of the world's
leading research institutions across Europe, North America, Asia
and Australasia. This expansion of sales and customer engagement in
India via GEHC builds on Feedback's existing strong customer
base.
Dr Balaji Ganeshan, Global Business Development Director of
Feedback Medical Ltd, said:
"This first purchase order of TexRAD(R) via GE Healthcare
represents an important milestone in our business relationship and
will help to grow our international reputation That one of India's
leading medical institutions has selected TexRAD(R) against other
image analysis candidates is a strong endorsement of our
technology."
For further information, please contact:
Feedback plc +44 (0)1954 718072
Alastair Riddell, Executive Chairman IR@fbk.com
Lindsay Melvin, CFO
Instinctif Partners +44 (0)20 7457 2020
Rozi Morris/ Deborah Bell feedbackplc@instinctif.com
Notes to editors
About Feedback plc
Feedback plc is a specialist medical imaging technology company.
It develops software and systems that provide innovative techniques
and improved workflows for practitioners involved in medical
research and treating patients. TexRAD(R) , the Company's patented
quantitative image texture analysis technology, has the potential
to assist clinicians in diagnosis, prognosis and treatment of
patients with cancer and is currently installed in over 50 of the
world's leading research institutions across Europe, North America,
Asia and Australasia. The Cadran platform provides a suite of
medical imaging tools for decision support. The Cadran range
includes the picture archiving communication system (PACS) to
provide decision support for scan analysis, diagnostic workstations
which provide secure remote access to view scans on demand, and
products to securely share and transport patient data. Visit
www.fbk.com.
About TexRAD(R) technology
TexRAD(R) is the Company's patented quantitative image texture
analysis technology for diagnostic radiological scans. The
technology has the potential to assist clinicians in diagnosis,
prognosis and treatment of patients with cancer, or other disease
indications, and is currently installed in over 50 of the world's
leading research institutions across Europe, North America, Asia
and Australasia. By analysing the texture features in computerised
tomography (CT) scans, magnetic resonance images (MRI) and positron
emission tomography scans (PET/CT), TexRAD's quantitative imaging
capabilities provide clinicians with additional, visually
imperceptible information to make better decisions in order to
improve patient outcomes.
TexRAD(R) research to date has shown great potential in many
different oncological and non-oncological sites. For example,
papers presented at RSNA 2017 focused on liver, pancreatic, kidney,
cervical, oral, genitourinary, head & neck, thyroid,
neuroendocrine and endometrial cancers, as well as gastrointestinal
stromal tumours, gliomas, thymic-epithelial neoplasms and
carotid-plaques. On 20 November 2017, Feedback announced the CE
marked release of TexRAD(R) Lung, a "software only" Class 1 medical
device, to help advance lung cancer diagnosis. Further information
on the TexRAD(R) technology can be found at www.fbk.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPIMRTMBBBBFP
(END) Dow Jones Newswires
August 15, 2018 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Okt 2023 bis Okt 2024